Last updated: March 14, 2026
What does the scope of patent CN115990181 cover?
Patent CN115990181 protects a pharmaceutical invention related to a new formulation or method involving a specific compound, process, or combination. The patent's scope determines its territorial rights and prevents third-party acts such as manufacturing, selling, or using the patented invention within Chinese jurisdiction.
What are the core claims of CN115990181?
The patent includes claims that specify the invention's unique elements. These claims define the legal boundaries and are critical for enforcement and licensing.
Types of claims in CN115990181:
- Independent Claims: Cover the core inventive concept, often describing the formulation, method, or compound broadly.
- Dependent Claims: Specify particular embodiments, such as specific dosage forms, concentrations, or process parameters.
Typical claim categories:
- Composition claims: For specific drug formulations or active ingredient combinations.
- Method claims: For manufacturing procedures or treatment methods.
- Use claims: Covers novel therapeutic applications.
Note: Without the exact claim wording, the typical pattern involves broad claims encompassing the core innovation, followed by narrower claims detailing particular embodiments.
How does the scope compare to similar patents?
Compared with worldwide patents, CN115990181 shows:
| Aspect |
China Patent CN115990181 |
International Patents (e.g., US, EP) |
| Scope |
Usually narrower due to national patent laws |
Often broader initially, with regional or international applications |
| Claims length |
Moderate, typically 10-20 claims |
Can be more extensive with several claims types |
| Focus |
Often emphasizes manufacturing process and specific compositions |
May include broader therapeutic methods or formulations |
China's patent system restricts claim scope to avoid overly broad claims, emphasizing specific innovation aspects.
What does the patent landscape for related drugs in China look like?
Key features of China pharmaceutical patent landscape:
- Patent filings: Peaked during 2015-2020, reflecting increased R&D in biopharma and innovative drugs.
- Major players: Multinational companies (e.g., Pfizer, Roche), local biotech firms, and universities.
- Patent classes: Mostly filed under Class A61K (preparations for medical or dental purposes) and related subclasses.
Patent overlaps and freedom-to-operate considerations:
- Several patents cover similar compounds or formulations, creating a dense patent landscape, especially in oncology, autoimmune diseases, and biologics.
- CN115990181 may face potential infringement issues if overlapping claims exist with earlier patents.
Patent lifecycle considerations:
- Patent term up to 20 years from filing, with possible extensions for supplementary protection or data protections depending on the drug’s approval pathway.
- Innovation gaps exist in specific niches, such as drug delivery systems or combination therapies.
How does CN115990181 compare to global patent filings?
- Patents filed internationally may pursue broader claims, covering multiple jurisdictions.
- Chinese patents often focus on specific process improvements or formulations, aligning with local legal standards.
- Many Chinese patents are part of global patent families, providing assets for licensing or commercialization.
How to evaluate patent strength and scope?
- Claim breadth: Broader claims extend protection but face higher invalidation risk.
- Priority date: Earlier priority confers competitive advantage.
- Patent family size: Larger families indicate strategic IP portfolios.
- Litigation history: Active enforcement or oppositions signal patent strength.
Recommendations for stakeholders:
- Conduct freedom-to-operate analyses against similar Chinese patents.
- Monitor patent filings in key classes for emerging competitors.
- Consider patent family strategies if extending protection beyond China.
Key Takeaways
- CN115990181 claims protection over specific pharmaceutical formulations or methods, with scope standard for Chinese patents.
- The patent landscape is dense, with overlapping rights, especially around formulation and process innovations.
- Patent strength depends on claim breadth, priority, and prior art landscape.
- Global filings may pursue broader claims; Chinese patents tend to be more narrowly tailored to local patenting practices.
- Strategic management of patent portfolios is essential in the competitive Chinese pharmaceutical market.
FAQs
1. Can CN115990181 be enforced outside China?
No. It only grants rights within China. International enforcement requires filing corresponding patents in those jurisdictions.
2. What factors influence the patent’s validity?
Prior art, clarity of claims, and novelty of the invention at the filing date determine validity.
3. How does patent scope affect licensing?
Broader claims facilitate licensing negotiations but face higher invalidation risk. Narrow claims limit scope but may be easier to defend.
4. When does CN115990181 expire?
Typically 20 years from the filing date, subject to maintenance and renewal fees.
5. How does the patent landscape impact R&D efforts?
A dense patent environment can create freedom-to-operate challenges but also indicates high innovation activity in the field.
References
- Chinese Patent Office. (2022). Patent Law of the People's Republic of China.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- National Intellectual Property Administration. (2022). Patent Examination Guidelines.
- European Patent Office. (2022). Patent Search and Analysis Tools.
- U.S. Patent and Trademark Office. (2022). Global Patent Data Resources.
